Characteristic
|
Group A: with ICI
(n=65)
|
Group B: without ICI
(n=62)
|
Age(years), median(range) |
60 (46-78) |
58(41-81) |
Gender, n(%) |
|
|
Male |
46 (70.8) |
41 (66.1) |
Female |
19 (29.2) |
21 (33.9) |
Tumor location, n(%) |
|
|
Right colon |
24 (36.9) |
19 (30.6) |
Left colon |
41 (63.1) |
43 (69.4) |
MMR, n(%) |
|
|
dMMR |
9 (13.8) |
0 |
pMMR |
56 (86.2) |
62 (100) |
KRAS, n(%) |
|
|
KRAS mutant |
37 (56.9) |
26 (41.9) |
KRAS wild |
28 (43.1) |
36 (58.1) |
Combined with targeted therapy, n(%) |
|
|
Yes |
24 (36.9) |
62 (100) |
No |
41 (63.1) |
0 |
Liver metastases, n(%) |
|
|
Yes |
51 (78.5) |
45 (72.6) |
No |
14 (21.5) |
17 (27.4) |
Lymph nodes metastases, n(%) |
|
|
Yes |
48 (73.8) |
41 (66.1) |
No |
17 (26.2) |
21 (33.9) |